Prefrontal Cortex Hippocampus Circuitry Gates Conditioned Fear

Propranolol, a beta-blocker commonly prescribed to control blood pressure, can prevent the reconsolidation of fear memories when administered while the memory is in edit mode. In rat studies, rats given Propranolol during memory retrieval behaved as if they had never learned to fear a frightening trigger cue. This finding was extended to humans, showing that Propranolol can destroy fear memories in healthy volunteers when the memory is destabilized.

Meryl Kent at the University of Amsterdam developed a treatment using reconsolidation to erase lifelong fears. The therapy involves triggering the fear memory, then administering propranolol, a blood-pressure medication that blocks the release of noradrenaline in the amygdala (the fear center of the brain). Since noradrenaline is part of the brain's anxiety signal during fearful events, blocking it after recall disrupts the reconsolidation process. This therapy has been tested on over 30 people with spider phobia and other anxiety disorders, with significant results showing patients no longer felt fear when exposed to the feared stimulus, even a year later.

Memory reconsolidation challenges the traditional view that consolidated memories remain fixed forever. When memories are recalled, they become temporarily unstable and require restabilization through protein synthesis. This creates a therapeutic window for intervention. A documented case study demonstrated overcoming a lifetime spider phobia in 24 hours: the participant first fully activated their fear memory by approaching and touching a tarantula, then received propranolol (a beta blocker that blocks protein synthesis) to prevent restabilization of the fear memory. One year later, the subject remained free of spider fear, demonstrating successful long-term modification of pathological memories through this mechanism.

Adrenaline strengthens emotional memory and allows better storage, while propranolol can inhibit this mechanism. In experiments, mice that received adrenaline after finding an island remembered it better, but when propranolol blocked adrenaline production, they no longer remembered the island. Normally, adrenaline binds to specific receptors generating stress, but propranolol binds to these same receptors, occupying them and preventing adrenaline access. This represents a breakthrough for PTSD treatment, offering two approaches: psychotherapy and medication.

Memory reconsolidation is a neurobiological process where recalled memories become temporarily unstable and malleable, creating a 'window of opportunity' lasting approximately 60-80 minutes. This discovery, made by researchers in the early 2000s, provides the scientific basis for therapeutic interventions. Propranolol, a beta-blocker originally used for high blood pressure, is administered before patients recall traumatic memories. The drug blocks protein synthesis in the brain during memory reconsolidation, effectively weakening the emotional intensity of the memory while preserving the factual content. This allows patients to remember the event without experiencing the same intense fear response.

EEG serves as a translational bridge in neuroimaging due to its high temporal resolution, low cost, and easy deployability. This makes it particularly valuable for studying populations with disadvantages, including lower and middle-income countries as well as disadvantaged populations within higher-income countries. The Global Brain Consortium has been moving toward this direction, positioning EEG as a practical tool for bridging research and clinical applications across diverse populations.

Neuroimaging techniques like EEG and fMRI allow psychologists to understand brain function by measuring different signals: EEG measures electrical changes from neuron communication, providing excellent timing information but poor spatial localization, while fMRI measures blood flow changes using powerful magnets, offering better spatial resolution but less precise timing; both techniques reveal cognitive processes such as stimulus evaluation (P3 component) and error detection (ERN component) through event-related potentials.

A research team from Korea University Medicine has identified a neuroimaging-based biomarker for Major Depressive Disorder (MDD) using the Local Gyrification Index (LGI), which measures cortical folding as a ratio of curved to smoothened cortical surfaces; their study revealed that MDD patients exhibited significantly lower LGI values in 7 out of 66 cortical regions, including the prefrontal cortex, anterior cingulate cortex, insula, and several temporal and parietal regions, with the most pronounced hypogyrification observed in the left parietal triangles.

Neuroimaging techniques such as functional magnetic resonance imaging (fMRI) and electroencephalography (EEG) have revolutionized the study of the mind in action. These tools allow researchers to observe brain activity in real-time, providing a unique window into understanding how neural networks collaborate to generate subjective human experiences.

This segment provides detailed explanations of two key neuroimaging technologies used in neuroeducation research. Functional MRI (fMRI) measures brain activity by detecting changes in blood flow and oxygenation, providing excellent spatial resolution to identify which brain regions activate during specific tasks. Electroencephalography (EEG) measures electrical activity produced by neurons, offering superior temporal resolution to capture rapid cognitive processes. The segment explains the trade-offs between these techniques: fMRI is better for mapping brain activation patterns, while EEG is more efficient for measuring processing speed.